Optimization of Vancomycin Dosing to Achieve Target Area Under the Curve in Pediatrics

Area of Science:

• Pharmacology
• Pediatric Infectious Diseases
• Clinical Pharmacokinetics

Background:

• Establishing optimal vancomycin dosing in pediatrics is crucial for treating serious infections.
• Historical vancomycin dosing recommendations may not achieve current target AUC/MIC ratios.
• Recent studies suggest higher vancomycin doses are necessary in pediatric populations.

Purpose of the Study:

• To determine pediatric vancomycin dosing requirements for achieving a target area under the curve to minimum inhibitory concentration (AUC/MIC) ratio.
• To evaluate how age and indication influence vancomycin dosage needs in children.
• To assess the incidence of nephrotoxicity associated with these higher vancomycin doses.

Main Methods:

• Retrospective analysis of 77 pediatric patients (1 month to 18 years) receiving intravenous vancomycin.
• Calculation of vancomycin AUC/MIC and assessment of dosing requirements based on age cohorts and indications.
• Monitoring for and evaluation of acute kidney injury as a measure of nephrotoxicity.

Main Results:

• The average vancomycin dose required to achieve the target AUC/MIC was 67.7 mg/kg/day.
• Dosing requirements varied significantly by age group, with younger children (1-5 years) needing higher doses (79 mg/kg/day) than older children (13-18 years, 53.9 mg/kg/day).
• Vancomycin dosing needs also differed significantly based on the indication for treatment, and acute kidney injury occurred in 6.5% of patients.

Conclusions:

• Pediatric vancomycin dosing to achieve target AUC/MIC ratios is significantly higher in younger patients, ranging from 53.9 to 79 mg/kg/day.
• These findings support recent guideline recommendations for increased vancomycin dosage in children.
• Adjusting doses for specific indications and continued monitoring are important, as nephrotoxicity rates remain low.